Welcome to our dedicated page for Insulet SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Insulet Corporation (NASDAQ: PODD) SEC filings, offering a structured view of the company’s regulatory disclosures as a NASDAQ-listed medical device manufacturer. Insulet develops the Omnipod tubeless insulin pump platform and the Omnipod 5 Automated Insulin Delivery System, and its filings help investors understand how this business is governed, financed, and overseen.
Through Forms 10-K and 10-Q, Insulet reports audited and interim financial statements, risk factors, and management’s discussion of its Omnipod product platform, manufacturing operations, and growth strategy in automated insulin delivery and related drug delivery applications. Current reports on Form 8-K disclose material events such as quarterly financial results, amendments to incentive and severance plans, executive leadership transitions, and appointments to the board of directors and committees.
Investors can also review proxy statements for details on executive and director compensation, governance structures, and shareholder matters, as well as any registration statements related to securities offerings. For monitoring insider activity, Forms 3, 4, and 5 report beneficial ownership and changes in holdings by Insulet’s officers, directors, and other insiders, which some investors use to gauge management’s alignment with shareholders.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify important changes in financial performance, risk disclosures, compensation arrangements, or governance. Real-time updates from the SEC’s EDGAR system ensure that new Insulet filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider transaction reports, appear promptly, while AI-generated explanations make complex regulatory language more accessible to a broad range of investors and researchers.
Insulet Corporation reported strong Q1 2026 results, with revenue of $761.7 million, up 33.9% from a year earlier, driven by 36.9% growth in Omnipod products and especially rapid international expansion.
Net income rose to $91.1 million and diluted EPS to $1.30, helped by higher volumes and pricing, partly offset by a lower gross margin of 69.5% due to increased inventory reserves and warranty costs from a voluntary Omnipod 5 medical device correction.
Operating cash flow was $113.8 million and free cash flow $89.5 million. Insulet ended the quarter with $480.4 million in cash and $948.1 million of net debt, and repurchased $300 million of stock under accelerated share repurchase agreements while extending and expanding its buyback authorization.
FMR LLC reported beneficial ownership of 3,963,512.09 shares of Insulet Corp common stock (CUSIP 45784P101), representing 5.6% of the class as of 03/31/2026. The cover data shows sole voting power of 3,727,171.97 and sole dispositive power of 3,963,512.09. The filing names Abigail P. Johnson as having dispositive power for the same share total and references a Power of Attorney and Exhibit 99 for related subsidiary and agreement information.
Insulet Corporation reported strong first quarter 2026 results with higher guidance for the year. Revenue reached $761.7 million, up 33.9% (or 30.1% in constant currency) and above the high end of its prior growth range. Omnipod revenue was $758.4 million, rising 36.9%, including $515.6 million from U.S. Omnipod, up 28.3%, and $242.9 million internationally, up 59.4%.
Operating income was $122.1 million, or 16.0% of revenue, while net income increased to $91.1 million, or $1.30 per diluted share, compared with $35.4 million and $0.50 a year earlier. Free cash flow was $89.5 million. The company repurchased 1.25 million shares and now expects full-year 2026 total revenue growth of 21%–23% in constant currency and adjusted EPS growth of more than 25%.
Insulet Corp Schedule 13G: Vanguard Capital Management reports beneficial ownership of 5,277,842 shares of Common Stock, representing 7.49% of the class as of 03/31/2026. The filing lists 698,568 shares with sole voting power and 5,277,842 shares with sole dispositive power.
The filing is signed by Ashley Grim as Head of Global Fund Administration on 04/30/2026.
Insulet Corporation furnished an update and clarification related to its voluntary Medical Device Correction. The Company previously reported 18 Serious Adverse Events and later expanded communications on April 10, 2026 to include 13 expired lots, stating this does not change its earlier estimated financial impact. The updated communication referenced 29 confirmed Serious Adverse Events. The Company also explained that an FDA website statement citing 476 serious injuries actually refers to 476 Medical Device Reports potentially related to the correction, rather than 29 confirmed Serious Adverse Events. The information is furnished under Item 7.01 and is not deemed filed under the Exchange Act.
Insulet Corporation reports strong 2025 growth and seeks shareholder approvals at its 2026 virtual annual meeting. Revenue reached about $2.7 billion with roughly 31% growth, gross margin was 71.6%, operating margin 17.5%, and free cash flow about $375 million, reflecting a highly profitable, recurring-revenue model.
The company highlights 10 consecutive years of at least 20% constant currency revenue growth, driven by Omnipod 5 adoption, global expansion and rising Type 2 diabetes use. The proxy asks shareholders to elect three Class I directors, approve executive pay on an advisory basis, and ratify the independent auditor. Insulet emphasizes a largely independent board, performance‑heavy executive compensation, formal clawback and stock ownership guidelines, and growing sustainability initiatives, including global Pod recycling and expanded renewable energy use.
Insulet Corp EVP and CCO Michael Panos received new equity awards. He was granted an employee stock option covering 7,255 shares of common stock at an exercise price of $207.04 per share, expiring on April 1, 2036. These non-qualified stock options become exercisable in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date.
He also received 2,777 restricted stock units that vest in substantially equal installments on each of the first, second and third anniversaries of the grant date and are settled one-for-one in common shares. Following these grants, he directly holds 2,782 shares of common stock and 7,255 stock options.
INSULET CORP executive Michael Panos filed an initial Form 3 reporting his holdings in the company. As EVP and Chief Commercial Officer, he disclosed direct beneficial ownership of 5 shares of INSULET CORP Common Stock. This filing records his starting equity position as an insider, without indicating any recent buy or sell transaction.
INSULET CORP director Robert Luther Huffines received an award of 111 deferred common stock units of Insulet common stock on March 31, 2026, valued at $209.84 per unit. This grant was made in lieu of cash board compensation under the company’s Deferred Compensation Plan for Non-Employee Directors and increased his reported holdings to 638 shares or units.
The deferred common stock units will convert into the same number of Insulet common shares upon distribution, with any fractional share value paid in cash. Distribution occurs at the director’s election, either in a lump sum or in substantially equal annual installments, consistent with the plan’s terms.
The Vanguard Group filed Amendment No. 14 to Schedule 13G/A reporting that it beneficially owns 0 shares of Insulet Corp Common Stock, representing 0% of the class as disclosed in the amendment.
The amendment explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that resulted in certain subsidiaries and business divisions of The Vanguard Group reporting ownership separately. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.